angiotensin ii has been researched along with Diabetic Angiopathies in 65 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (9.23) | 18.7374 |
| 1990's | 8 (12.31) | 18.2507 |
| 2000's | 38 (58.46) | 29.6817 |
| 2010's | 13 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jang, HC; Kim, KM; Kong, SH; Lee, DH; Lee, JE; Lim, S; Min, SH; Oh, TJ; Park, KS | 1 |
| Cosic, A; Drenjancevic, I; Falck, JR; Kibel, A; Mihaljevic, Z; Novak, S | 1 |
| De Mello, WC | 1 |
| Cai, L; Hein, DW; Li, X; Marshall, JP; Prabhu, SD; Xiang, X; Zhou, G | 1 |
| Gao, L; Mann, GE | 1 |
| Szabo, C | 1 |
| De Geest, B; Egorova, M; Jacobs, F; Lorenz, M; Meloni, M; Schultheiss, HP; Spillmann, F; Stangl, V; Tschöpe, C; Van Linthout, S | 1 |
| Ishida, K; Kamata, K; Kobayashi, T; Matsumoto, T; Nakayama, N | 1 |
| Hayashi, T; Takai, S; Yamashita, C | 1 |
| Bivona, BJ; Chappell, MC; Harrison-Bernard, LM; Kobori, H; Lazartigues, E; Park, S; Seth, DM | 1 |
| Chai, Q; He, T; Katusic, ZS; Lee, HC; Lu, T; Wang, RX; Wang, XL; Zhang, DM | 1 |
| Angeli, F; Garofoli, M; Gentile, G; Martire, P; Mazzotta, G; Reboldi, G; Verdecchia, P | 1 |
| Kamata, K; Kobayashi, T; Matsumoto, T; Nemoto, S; Taguchi, K | 1 |
| Chen, J; Chopp, M; Cui, X; Cui, Y; Liu, X; Lu, M; Roberts, C; Shehadah, A; Yan, T; Ye, X; Zacharek, A | 1 |
| Collier, P; McDonald, KM | 1 |
| Kamata, K; Kobayashi, T; Matsumoto, T; Taguchi, K | 1 |
| Basu, R; Bodiga, S; Das, SK; Grant, MB; Kassiri, Z; Lo, J; Oudit, GY; Patel, VB; Wang, W; Wang, Z; Zhong, J | 1 |
| Lopaschuk, GD; Ussher, JR | 1 |
| Cooper, ME; Du, XJ; Head, GA; Kiriazis, H; Nguyen-Huu, TP; Pickering, R; Thomas, MC; Tikellis, C; Tsorotes, D | 1 |
| Hulthén, UL | 1 |
| Kalantarinia, K; Siragy, HM | 1 |
| Berl, T; Drury, PL; Esmatjes, E; Goldhaber, SZ; Hricik, D; Hunsicker, LG; Lewis, EJ; Lewis, JB; Locatelli, F; Parikh, CR; Pfeffer, MA; Porush, JG; Raz, I; Rouleau, JL; Vanhille, P; Wiegmann, TB; Wolfe, BM | 1 |
| Hayward, RA; Vijan, S | 1 |
| Gilbert, RE; Kelly, DJ; Krum, H; Wilkinson-Berka, J | 1 |
| Endoh, S; Hayashi, T; Kitaura, Y; Mori, T; Okabe, M; Shimomura, H; Sohmiya, K; Terasaki, F; Ukimura, A | 1 |
| Marshall, SM | 1 |
| Berghold, A; Horvath, K; Pieber, TR; Plank, J; Siebenhofer, A; Sommer, R; Sutton, AJ | 1 |
| Donnelly, R; Gray, S; Idris, I | 1 |
| Fujita, T; Hirata, Y; Kitamura, T; Nagai, R; Nishimatsu, H; Omata, M; Satonaka, H; Suzuki, E; Takeda, R | 1 |
| Inoguchi, T; Nawata, H | 1 |
| Chaturvedi, N; Deinum, J | 1 |
| Huang, XR; Kim-Mitsuyama, S; Koka, V; Lan, HY; Truong, LD; Wang, W | 1 |
| Chiarelli, F; Di Marzio, D; Giannini, C; Mohn, A; Mokini, ZH | 1 |
| Komuro, I; Minamino, T | 1 |
| Huang, Y; Lau, CW; Lin, SG; Yu, XY; Yung, LM; Zhong, JC | 1 |
| Banes-Berceli, AK; Ketsawatsomkron, P; Marrero, MB; Ogbi, S; Patel, B; Pollock, DM | 1 |
| Morris, AD; Sharman, DC; Struthers, AD | 1 |
| Boyle, PJ | 1 |
| Liu, Z | 1 |
| Fulton, D; Marrero, MB; Stepp, D; Stern, DM | 1 |
| Davies, J; George, J; Morris, AD; Rajendra, NS; Struthers, AD; Swaminathan, K | 1 |
| Drury, PL | 1 |
| Beretta-Piccoli, C; Weidmann, P | 1 |
| Dawson, D; Denver, E; Foyle, WJ; Pinkney, J; Sampson, MJ; Yudkin, JS | 1 |
| Burden, AC; Hearnshaw, JR; McNally, PG; Rimmer, T; Thurston, H; Watt, PA | 1 |
| Leese, GP; Vora, JP | 1 |
| Cooper, ME; Komers, R; Rumble, JR | 1 |
| Hamaguchi, A; Iwao, H; Kim, S; Miura, K; Wanibuchi, H; Yamanaka, S | 1 |
| McCarty, MF | 1 |
| González-Juanatey, JR | 1 |
| Schrier, RW | 1 |
| Flack, JM | 1 |
| Andreoli, AM; Anversa, P; Chimenti, S; Fiordaliso, F; Kajstura, J; Leri, A; Li, B; Limana, F; Medow, MS; Nadal-Ginard, B | 1 |
| Brands, MW; Fitzgerald, SM | 1 |
| Brenner, BM; Cooper, ME; de Zeeuw, D; Keane, WF; Mitch, WE; Parving, HH; Remuzzi, G; Shahinfar, S; Snapinn, SM; Zhang, Z | 1 |
| Andersen, S; Arner, P; Brøchner-Mortensen, J; Gomis, R; Lehnert, H; Parving, HH | 1 |
| Srivastava, AK | 1 |
| Dell'Italia, LJ; Lucchesi, PA; Rocic, P | 1 |
| Gordon, MS; Hollenberg, NK; Price, DA | 1 |
| Antonini, P; Beretta-Piccoli, C; Bernasconi-Zapf, M; Kressebuch, H; Pianezzi, F; Ziegler, WH | 1 |
| Aurell, M; Björck, S | 1 |
| Brenner, BM; Zatz, R | 1 |
| Trost, BN; Weidmann, P | 1 |
| Morandini, G; Palmas, S; Piras, L | 1 |
| Gligore, V; Holan, T; Lucaciu, O | 1 |
23 review(s) available for angiotensin ii and Diabetic Angiopathies
| Article | Year |
|---|---|
Vascular NAD(P)H oxidase activation in diabetes: a double-edged sword in redox signalling.
Topics: Angiotensin II; Animals; Antioxidants; Diabetic Angiopathies; Diabetic Nephropathies; Endothelium, Vascular; Enzyme Activation; Glycation End Products, Advanced; Humans; Insulin Resistance; Mitochondria; NADPH Oxidases; NF-E2-Related Factor 2; Nitric Oxide Synthase Type III; Oxidation-Reduction; Oxidative Stress; Protein Kinase C; Reactive Oxygen Species; Signal Transduction | 2009 |
Role of nitrosative stress in the pathogenesis of diabetic vascular dysfunction.
Topics: Aldehyde Reductase; Angiotensin II; Animals; Diabetic Angiopathies; Drug Therapy, Combination; Endothelium, Vascular; Enzyme Activation; Glucose; Glycation End Products, Advanced; Humans; Oxidative Stress; Peroxynitrous Acid; Poly Adenosine Diphosphate Ribose; Protein Kinase C; Reactive Nitrogen Species; Reactive Oxygen Species; Signal Transduction | 2009 |
Impact of the renin-angiotensin-aldosterone-system on cardiovascular and renal complications in diabetes mellitus.
Topics: Aldosterone; Angiotensin II; Animals; Cardiovascular Diseases; Chymases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Nephropathies; Humans; Oxidative Stress; Renin-Angiotensin System | 2010 |
Aliskiren versus ramipril in hypertension.
Topics: Aging; Amides; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Diabetic Angiopathies; Fumarates; Half-Life; Humans; Hypertension; Ramipril; Renin-Angiotensin System | 2010 |
Nephrin: a pivotal molecule in proteinuria influenced by angiotensin II.
Topics: Albuminuria; Angiotensin II; Animals; Diabetic Angiopathies; Humans; Hypertension; Membrane Proteins; Proteins; Proteinuria | 2003 |
The choice of antihypertensive drugs in patients with diabetes: angiotensin II and beyond.
Topics: Angiotensin II; Antihypertensive Agents; Diabetic Angiopathies; Humans; Hypertension; Renin-Angiotensin System | 2002 |
Treatment of hypertension in type 2 diabetes mellitus: blood pressure goals, choice of agents, and setting priorities in diabetes care.
Topics: Adrenergic beta-Antagonists; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzothiadiazines; Blood Pressure; Calcium Channel Blockers; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diuretics; Evidence-Based Medicine; Humans; Hypertension; Randomized Controlled Trials as Topic; Sodium Chloride Symporter Inhibitors | 2003 |
The renin-angiotensin system and the long-term complications of diabetes: pathophysiological and therapeutic considerations.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Diabetic Angiopathies; Diabetic Nephropathies; Diabetic Retinopathy; Growth Substances; Humans; Renin-Angiotensin System | 2003 |
Angiotensin receptor blockers as anti-hypertensive treatment for patients with diabetes mellitus: meta-analysis of controlled double-blind randomized trials.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Diabetic Angiopathies; Diabetic Nephropathies; Double-Blind Method; Humans; Kidney Failure, Chronic; Morbidity; Randomized Controlled Trials as Topic | 2004 |
NAD(P)H oxidase activation: a potential target mechanism for diabetic vascular complications, progressive beta-cell dysfunction and metabolic syndrome.
Topics: Adipocytes; Angiotensin II; Animals; Diabetic Angiopathies; Enzyme Activation; Enzyme Inhibitors; Humans; Islets of Langerhans; Metabolic Syndrome; NADPH Oxidases; Oxidative Stress; Protein Kinase C | 2005 |
The Renin-Angiotensin system and vascular disease in diabetes.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Diabetic Angiopathies; Diabetic Nephropathies; Diabetic Retinopathy; Humans; Renin-Angiotensin System | 2002 |
Macroangiopathy in adults and children with diabetes: from molecular mechanisms to vascular damage (part 1).
Topics: Adult; Angiotensin I; Angiotensin II; Atherosclerosis; Child; Cholesterol, LDL; Diabetic Angiopathies; Fatty Liver; Humans; Inflammation; Macrophages; Thrombosis | 2006 |
Vascular cell senescence: contribution to atherosclerosis.
Topics: Aging; Aging, Premature; Angiotensin II; Animals; Atherosclerosis; Blood Vessels; Cellular Senescence; Diabetic Angiopathies; DNA Damage; Humans; Mitochondria; Oxidative Stress; Syndrome; Telomere | 2007 |
Diabetes mellitus and macrovascular disease: mechanisms and mediators.
Topics: Adiponectin; Angiotensin II; Animals; Atherosclerosis; Blood Coagulation; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Humans; Insulin Resistance; Peroxisome Proliferator-Activated Receptors | 2007 |
Angiotensin II-induced signaling pathways in diabetes.
Topics: Angiotensin II; Cell Division; Diabetes Mellitus; Diabetic Angiopathies; Diabetic Nephropathies; Glomerular Mesangium; Glycation End Products, Advanced; Humans; Hyperglycemia; Muscle, Smooth, Vascular; Reactive Oxygen Species; Signal Transduction | 2005 |
Diabetes and arterial hypertension.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aging; Angiotensin II; Antihypertensive Agents; Blood Pressure; Catecholamines; Diabetes Mellitus; Diabetic Angiopathies; Diabetic Nephropathies; Diabetic Retinopathy; Diuretics; Female; Humans; Hypertension; Insulin; Male; Middle Aged; Obesity; Renin; Sodium; Systole; Vascular Diseases | 1983 |
The management of hypertension in diabetes: with special reference to diabetic kidney disease.
Topics: Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Blood Pressure; Catecholamines; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Retinopathy; Glomerular Filtration Rate; Hypertension | 1996 |
[Do angiotensin II receptor antagonists substitute angiotensin converting enzyme inhibitors in the treatment of high blood pressure?].
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Diabetic Angiopathies; Heart Failure; Humans; Hypertension; Hypertrophy, Left Ventricular; Vasoconstriction | 2000 |
Treating high-risk diabetic hypertensive patients with comorbid conditions.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Glucose; Blood Pressure; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Complications; Diabetes Mellitus; Diabetic Angiopathies; Disease Progression; Humans; Hypertension; Kidney Failure, Chronic; Randomized Controlled Trials as Topic; Renin-Angiotensin System; Risk Factors | 2000 |
Arterial pressure control at the onset of type I diabetes: the role of nitric oxide and the renin-angiotensin system.
Topics: Angiotensin II; Animals; Blood Pressure; Cardiovascular System; Diabetes Mellitus, Type 1; Diabetic Angiopathies; Humans; Hypertension; Kidney; Nitric Oxide; Renin-Angiotensin System | 2001 |
High glucose-induced activation of protein kinase signaling pathways in vascular smooth muscle cells: a potential role in the pathogenesis of vascular dysfunction in diabetes (review).
Topics: Angiotensin II; Animals; Diabetes Mellitus; Diabetic Angiopathies; Enzyme Activation; Hyperglycemia; MAP Kinase Signaling System; Mitogen-Activated Protein Kinases; Muscle, Smooth, Vascular; NF-kappa B; Protein Kinase C | 2002 |
Diabetes mellitus, the renin-angiotensin system, and angiotensin-converting enzyme inhibition.
Topics: Aldosterone; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Pressure; Diabetes Mellitus, Experimental; Diabetic Angiopathies; Humans; Hypertension; Kidney; Rats; Receptors, Angiotensin; Renin; Sodium | 1990 |
Pathogenesis of diabetic microangiopathy. The hemodynamic view.
Topics: Angiotensin II; Animals; Basement Membrane; Blood Pressure; Capillaries; Capillary Permeability; Catecholamines; Diabetes Mellitus, Experimental; Diabetic Angiopathies; Hemodynamics; Humans; Hypertension; Hypoxia; Kidney Glomerulus; Microcirculation; Prostaglandins; Rats; Receptors, Angiotensin; Renin-Angiotensin System; Retinal Vessels; Vasodilation | 1986 |
5 trial(s) available for angiotensin ii and Diabetic Angiopathies
| Article | Year |
|---|---|
Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy.
Topics: Amlodipine; Angiotensin II; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Calcium Channel Blockers; Cardiovascular Diseases; Creatinine; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Nephropathies; Double-Blind Method; Female; Follow-Up Studies; Humans; Hypertension; Irbesartan; Kidney Failure, Chronic; Male; Middle Aged; Placebos; Risk Factors; Tetrazoles; Treatment Outcome | 2003 |
Gradual reactivation of vascular angiotensin I to angiotensin II conversion during chronic ACE inhibitor therapy in patients with diabetes mellitus.
Topics: Adult; Aged; Aldosterone; Angiotensin I; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Blood Flow Velocity; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Humans; Hypertension; Kinetics; Lisinopril; Male; Middle Aged | 2007 |
Spironolactone for poorly controlled hypertension in type 2 diabetes: conflicting effects on blood pressure, endothelial function, glycaemic control and hormonal profiles.
Topics: Aged; Aldosterone; Angiotensin II; Blood Glucose; Blood Pressure; Body Mass Index; Cross-Over Studies; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Double-Blind Method; Endothelium, Vascular; Female; Fibroblast Growth Factors; Glycated Hemoglobin; Humans; Hydrocortisone; Hypertension; Male; Middle Aged; Natriuretic Peptide, Brain | 2008 |
[Effect of losartan on renal and cardiovascular complications of patients with type 2 diabetes and nephropathy].
Topics: Adult; Aged; Angiotensin II; Antihypertensive Agents; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Nephropathies; Double-Blind Method; Humans; Losartan; Male; Middle Aged; Renin-Angiotensin System | 2001 |
[Effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes].
Topics: Adult; Aged; Albuminuria; Angiotensin II; Antihypertensive Agents; Biphenyl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Nephropathies; Double-Blind Method; Female; Follow-Up Studies; Humans; Irbesartan; Male; Middle Aged; Renin-Angiotensin System; Tetrazoles | 2001 |
37 other study(ies) available for angiotensin ii and Diabetic Angiopathies
| Article | Year |
|---|---|
Association of angiotensin-II levels with albuminuria in subjects with normal glucose metabolism, prediabetes, and type 2 diabetes mellitus.
Topics: Aged; Albuminuria; Angiotensin II; Biomarkers; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Nephropathies; Early Diagnosis; Endothelium, Vascular; Female; Hospitals, University; Humans; Insulin Resistance; Male; Microvessels; Middle Aged; Outpatient Clinics, Hospital; Prediabetic State; Republic of Korea; Risk Factors; Up-Regulation; Vasculitis | 2017 |
Hyperbaric oxygenation modulates vascular reactivity to angiotensin-(1-7) in diabetic rats: potential role of epoxyeicosatrienoic acids.
Topics: 8,11,14-Eicosatrienoic Acid; Amides; Angiotensin I; Angiotensin II; Animals; Aorta, Thoracic; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 Enzyme System; Cytochrome P450 Family 2; Diabetes Mellitus, Type 1; Diabetic Angiopathies; Enzyme Induction; Enzyme Inhibitors; Hyperbaric Oxygenation; Male; Oxidative Stress; Peptide Fragments; Rats, Sprague-Dawley; Steroid 16-alpha-Hydroxylase; Vascular Resistance; Vasoconstriction; Vasodilation; Vasodilator Agents | 2015 |
Metallothionein reverses the harmful effects of angiotensin II on the diabetic heart.
Topics: Angiotensin II; Cardiomyopathies; Diabetic Angiopathies; Humans; Metallothionein; NADP; Oxidative Stress | 2008 |
Metallothionein suppresses angiotensin II-induced nicotinamide adenine dinucleotide phosphate oxidase activation, nitrosative stress, apoptosis, and pathological remodeling in the diabetic heart.
Topics: Angiotensin II; Animals; Apoptosis; Cardiomyopathies; Diabetes Mellitus, Experimental; Diabetic Angiopathies; Fibrosis; Hypertrophy; Metallothionein; Mice; Mice, Transgenic; Myocardium; Myocytes, Cardiac; NADP; Oxidative Stress; Ventricular Remodeling | 2008 |
Vascular-protective effects of high-density lipoprotein include the downregulation of the angiotensin II type 1 receptor.
Topics: Angiotensin II; Animals; Aorta; Apolipoprotein A-I; Diabetes Mellitus, Experimental; Diabetic Angiopathies; Dimerization; Down-Regulation; Endothelium, Vascular; Gene Transfer Techniques; Humans; Hyperglycemia; Lipoproteins, HDL; Male; NADPH Oxidase 4; NADPH Oxidases; Nitric Oxide Synthase Type III; Oxidative Stress; Rats; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; Signal Transduction | 2009 |
Involvement of NO and MEK/ERK pathway in enhancement of endothelin-1-induced mesenteric artery contraction in later-stage type 2 diabetic Goto-Kakizaki rat.
Topics: Angiotensin II; Animals; Arginine Vasopressin; Butadienes; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Disease Models, Animal; Disease Progression; Dose-Response Relationship, Drug; Endothelin-1; Endothelins; Enzyme Inhibitors; Extracellular Signal-Regulated MAP Kinases; Flavonoids; Male; MAP Kinase Kinase Kinases; Mesenteric Arteries; Nitric Oxide; Nitric Oxide Donors; Nitric Oxide Synthase; Nitriles; Nitroarginine; Nitroprusside; Oligopeptides; Peptide Fragments; Peptides, Cyclic; Piperidines; Rats; Rats, Wistar; Receptor, Endothelin A; Receptor, Endothelin B; Signal Transduction; Vasoconstriction; Vasodilation | 2009 |
Major role for ACE-independent intrarenal ANG II formation in type II diabetes.
Topics: Angiotensin I; Angiotensin II; Angiotensin-Converting Enzyme 2; Angiotensinogen; Animals; Arterioles; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Disease Models, Animal; Kidney; Male; Mice; Mice, Mutant Strains; Peptidyl-Dipeptidase A; Rats; Rats, Sprague-Dawley; Receptors, Leptin; Serine Proteases; Signal Transduction; Vasoconstriction | 2010 |
Regulation of coronary arterial BK channels by caveolae-mediated angiotensin II signaling in diabetes mellitus.
Topics: Angiotensin II; Animals; Caveolae; Caveolin 1; Coronary Vessels; CSK Tyrosine-Protein Kinase; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetic Angiopathies; Enzyme Inhibitors; GTP-Binding Protein alpha Subunits, Gq-G11; Large-Conductance Calcium-Activated Potassium Channels; Male; Membrane Potentials; Mice; Mice, Knockout; Muscle, Smooth, Vascular; NADH, NADPH Oxidoreductases; NADPH Oxidase 1; Oxidation-Reduction; Patch-Clamp Techniques; Phosphorylation; Potassium; Protein Processing, Post-Translational; Protein-Tyrosine Kinases; Rats; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; Signal Transduction; src-Family Kinases; Time Factors; Vasoconstriction | 2010 |
Losartan improves aortic endothelium-dependent relaxation via proline-rich tyrosine kinase 2/Src/Akt pathway in type 2 diabetic Goto-Kakizaki rats.
Topics: 3-Phosphoinositide-Dependent Protein Kinases; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Aorta; Blotting, Western; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Disease Models, Animal; Dose-Response Relationship, Drug; Endothelium, Vascular; Focal Adhesion Kinase 2; Immunohistochemistry; Insulin; Insulin Receptor Substrate Proteins; Insulin Resistance; Losartan; Nitric Oxide; Nitric Oxide Synthase Type III; Phosphatidylinositol 3-Kinase; Phosphorylation; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins c-akt; Rats; Rats, Wistar; Signal Transduction; src-Family Kinases; Vasodilation; Vasodilator Agents | 2011 |
Niaspan enhances vascular remodeling after stroke in type 1 diabetic rats.
Topics: Angiotensin I; Angiotensin II; Animals; Blood Glucose; Blood-Brain Barrier; Cerebral Hemorrhage; Cerebrovascular Circulation; Cholesterol, HDL; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetic Angiopathies; Disease Models, Animal; Infarction, Middle Cerebral Artery; Male; Niacin; Rats; Rats, Wistar; Vasodilator Agents | 2011 |
The role of renin angiotensin system intervention in stage B heart failure.
Topics: Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Diabetic Angiopathies; Heart Failure; Humans; Myocardial Infarction; Myocardial Ischemia; Renin-Angiotensin System; Signal Transduction; Stroke Volume; Ventricular Dysfunction, Left | 2012 |
Angiotensin II type 2 receptor-dependent increase in nitric oxide synthase activity in the endothelium of db/db mice is mediated via a MEK pathway.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Aorta; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Disease Models, Animal; Dose-Response Relationship, Drug; Endothelium, Vascular; Enzyme Activation; Flavonoids; Losartan; Male; MAP Kinase Kinase 1; MAP Kinase Kinase 2; MAP Kinase Kinase Kinases; Mice; Mice, Inbred C57BL; Nitric Oxide; Nitric Oxide Synthase Type III; Oligopeptides; Phosphorylation; Protein Kinase Inhibitors; Receptor, Angiotensin, Type 2; Signal Transduction; Time Factors; Vasodilation; Vasodilator Agents | 2012 |
Loss of angiotensin-converting enzyme-2 exacerbates diabetic cardiovascular complications and leads to systolic and vascular dysfunction: a critical role of the angiotensin II/AT1 receptor axis.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme 2; Animals; Diabetic Angiopathies; Female; Gene Expression; Heart Failure, Systolic; Male; Matrix Metalloproteinases; Mice; Mice, Knockout; NADPH Oxidases; Oxidative Stress; Peptidyl-Dipeptidase A; Receptor, Angiotensin, Type 1; Renin-Angiotensin System; Sarcoplasmic Reticulum Calcium-Transporting ATPases; Signal Transduction | 2012 |
An ACE up your sleeve: 2 is better than 1.
Topics: Angiotensin II; Angiotensin-Converting Enzyme 2; Animals; Diabetic Angiopathies; Female; Male; Peptidyl-Dipeptidase A; Receptor, Angiotensin, Type 1 | 2012 |
Interaction of diabetes and ACE2 in the pathogenesis of cardiovascular disease in experimental diabetes.
Topics: Angiotensin II; Angiotensin-Converting Enzyme 2; Animals; Aortic Diseases; Apoptosis; Biomarkers; Blood Pressure; Cardiovascular Diseases; Diabetes Mellitus, Experimental; Diabetic Angiopathies; Inflammation Mediators; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Myocardium; Peptidyl-Dipeptidase A; Plaque, Atherosclerotic; Telemetry | 2012 |
Angiotensin II receptor blockade prevents microangiopathy and preserves diastolic function in the diabetic rat heart.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Benzimidazoles; Biphenyl Compounds; Blood Glucose; Body Weight; Capillaries; Cytokines; Diabetic Angiopathies; Heme Oxygenase (Decyclizing); Immunohistochemistry; Male; Matrix Metalloproteinases; Organ Size; Rats; Rats, Inbred OLETF; Reverse Transcriptase Polymerase Chain Reaction; Tetrazoles; Tissue Inhibitor of Metalloproteinase-2; Ventricular Dysfunction, Left | 2003 |
Inhibition of the renin-angiotensin system: added value in reducing cardiovascular and renal risk?
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Diabetes Mellitus; Diabetic Angiopathies; Diabetic Nephropathies; Humans; Renal Insufficiency; Renin-Angiotensin System; Risk Factors | 2004 |
Protein kinase C-beta inhibition and diabetic microangiopathy: effects on endothelial permeability responses in vitro.
Topics: Angiotensin II; Capillary Permeability; Diabetic Angiopathies; Endothelium, Vascular; Enzyme Inhibitors; Glucose; Humans; Mesylates; Protein Kinase C; Protein Kinase C beta; Pyrroles | 2004 |
Endothelial dysfunction and hypercontractility of vascular myocytes are ameliorated by fluvastatin in obese Zucker rats.
Topics: Adrenomedullin; Angiotensin II; Animals; Aorta; Calcium; Diabetic Angiopathies; Endothelium, Vascular; Fatty Acids, Monounsaturated; Fluvastatin; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Nitric Oxide Synthase; Nitric Oxide Synthase Type III; Obesity; Peptides; Phosphorylation; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Rats; Rats, Zucker; rho GTP-Binding Proteins; Vasoconstriction; Vasoconstrictor Agents; Vasodilation; Vasodilator Agents | 2005 |
Advanced glycation end products activate a chymase-dependent angiotensin II-generating pathway in diabetic complications.
Topics: Adult; Aged; Angiotensin II; Chymases; Diabetic Angiopathies; Female; Glycation End Products, Advanced; Humans; Hypertension; Male; Middle Aged; Mitogen-Activated Protein Kinase 3; Muscle, Smooth, Vascular; Receptor for Advanced Glycation End Products; Receptors, Immunologic; Serine Endopeptidases; Up-Regulation | 2006 |
Apelin modulates aortic vascular tone via endothelial nitric oxide synthase phosphorylation pathway in diabetic mice.
Topics: Acetylcholine; Adipokines; Angiotensin II; Animals; Aorta; Apelin; Apelin Receptors; Blotting, Western; Carrier Proteins; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Humans; In Vitro Techniques; Intercellular Signaling Peptides and Proteins; Mice; Mice, Inbred Strains; Models, Animal; Muscle, Smooth, Vascular; NG-Nitroarginine Methyl Ester; Nitric Oxide Synthase Type III; Phosphorylation; Proto-Oncogene Proteins c-akt; Receptors, G-Protein-Coupled; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Vasodilation; Vasodilator Agents | 2007 |
Angiotensin II and endothelin-1 augment the vascular complications of diabetes via JAK2 activation.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Aorta, Thoracic; Atrasentan; Benzimidazoles; Biphenyl Compounds; Blood Glucose; Blood Pressure; Diabetes Mellitus, Experimental; Diabetic Angiopathies; Endothelin A Receptor Antagonists; Endothelin-1; Enzyme Activation; Intracellular Signaling Peptides and Proteins; Janus Kinase 2; Male; Phosphorylation; Protein Kinase Inhibitors; Protein Tyrosine Phosphatase, Non-Receptor Type 1; Protein Tyrosine Phosphatase, Non-Receptor Type 11; Protein Tyrosine Phosphatase, Non-Receptor Type 6; Protein Tyrosine Phosphatases; Pyrrolidines; Rats; Receptor, Angiotensin, Type 1; Receptor, Endothelin A; Signal Transduction; STAT1 Transcription Factor; STAT3 Transcription Factor; Tetrazoles; Time Factors; Tyrphostins; Vasodilation | 2007 |
Research profile. Places in the heart. Pinpointing the cause of cardiovascular complications.
Topics: Angiotensin II; Cardiovascular Diseases; Diabetic Angiopathies; Humans; Insulin Resistance | 2007 |
Exaggerated pressor responsiveness to norepinephrine in nonazotemic diabetes mellitus.
Topics: Adult; Angiotensin II; Blood Pressure; Diabetes Mellitus; Diabetic Angiopathies; Female; Humans; Hypertension; Male; Middle Aged; Norepinephrine; Pressoreceptors | 1981 |
Association between left ventricular hypertrophy and erythrocyte sodium-lithium exchange in normotensive subjects with and without NIDDM.
Topics: Adult; Aged; Albuminuria; Angiotensin II; Antiporters; Blood Pressure; Body Mass Index; Chi-Square Distribution; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Echocardiography, Doppler, Pulsed; Epinephrine; Erythrocytes; Female; Glycated Hemoglobin; Heart Rate; Humans; Hypertrophy, Left Ventricular; Insulin; Lithium; Male; Middle Aged; Norepinephrine; Regression Analysis; Sodium | 1995 |
Impaired contraction and endothelium-dependent relaxation in isolated resistance vessels from patients with insulin-dependent diabetes mellitus.
Topics: Acetylcholine; Adult; Angiotensin II; Arteries; Bradykinin; Diabetes Mellitus, Type 1; Diabetic Angiopathies; Endothelium, Vascular; Female; Humans; In Vitro Techniques; Male; Muscle Contraction; Muscle, Smooth, Vascular; Nitroprusside; Norepinephrine; Potassium; Vascular Resistance; Vasoconstriction | 1994 |
Kinins or nitric oxide, or both, are involved in the antitrophic effects of angiotensin converting enzyme inhibitors on diabetes-associated mesenteric vascular hypertrophy in the rat.
Topics: Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Arginine; Bradykinin; Diabetic Angiopathies; Hypertrophy; Indoles; Kinins; Male; Mesenteric Arteries; Nitric Oxide; Nitroarginine; Perindopril; Rats; Rats, Wistar | 1996 |
Angiotensin blockade improves cardiac and renal complications of type II diabetic rats.
Topics: Albuminuria; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Pressure; Cilazapril; Coronary Vessels; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Nephropathies; Glucose Tolerance Test; Imidazoles; Insulin; Male; Proteinuria; Pyridines; Rats; Rats, Inbred Strains | 1997 |
A central role for protein kinase C overactivity in diabetic glomerulosclerosis: implications for prevention with antioxidants, fish oil, and ACE inhibitors.
Topics: Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Antioxidants; Diabetic Angiopathies; Diabetic Nephropathies; Enzyme Activation; Fish Oils; Heparitin Sulfate; Humans; Hyperglycemia; Kidney Glomerulus; Lipid Peroxidation; Models, Biological; Nitric Oxide; Protein Kinase C; Thromboxane A2; Transforming Growth Factor beta | 1998 |
Minimizing the progression of kidney disease. Introduction.
Topics: Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Diabetic Angiopathies; Disease Progression; Diuretics; Humans; Hypertension; Kidney Diseases; Kidney Failure, Chronic; Patient Care Planning; Renin-Angiotensin System | 2000 |
IGF-1 overexpression inhibits the development of diabetic cardiomyopathy and angiotensin II-mediated oxidative stress.
Topics: Angiotensin II; Animals; Apoptosis; Cardiomyopathies; Diabetic Angiopathies; DNA; Insulin-Like Growth Factor I; Mice; Mice, Transgenic; Myocardium; Oxidative Stress; Reactive Oxygen Species; Renin-Angiotensin System; Tissue Distribution; Tumor Suppressor Protein p53; Tyrosine; Ventricular Function | 2001 |
Use of angiotensin-converting enzyme inhibitors in patients with diabetes and coronary artery disease.
Topics: Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Bradykinin; Chymases; Coronary Artery Disease; Diabetic Angiopathies; Endothelium, Vascular; Fibrinolysis; Humans; Losartan; Oxidative Stress; Serine Endopeptidases | 2002 |
Blunted suppression of plasma renin activity in diabetes.
Topics: Adult; Angiotensin II; Blood Pressure; Diabetes Mellitus, Type 1; Diabetic Angiopathies; Diet, Sodium-Restricted; Feedback; Female; Humans; Hypertension; Male; Middle Aged; Reference Values; Renin | 2000 |
Cardiovascular regulation during angiotensin converting enzyme inhibition with captopril in diabetes-associated hypertension.
Topics: Adult; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Captopril; Diabetic Angiopathies; Female; Humans; Hypertension; Male; Middle Aged; Norepinephrine; Renin; Sodium; Time Factors | 1990 |
Pathogenesis and treatment of hypertension associated with diabetes.
Topics: Angiotensin II; Blood Pressure; Diabetic Angiopathies; Humans; Hypertension; Norepinephrine; Renin-Angiotensin System; Risk; Smoking; Sodium; Sympathetic Nervous System; Water-Electrolyte Balance | 1985 |
[Study on peripheral vascular reactivity to angiotensin and noradrenalin in subjects with diabetes mellitus].
Topics: Adolescent; Adult; Aged; Angiotensin II; Child; Diabetes Mellitus; Diabetic Angiopathies; Female; Humans; Male; Middle Aged; Norepinephrine; Skin Tests | 1965 |
[Studies of the early diagnosis of diabetic microangiopathies, using the skin clearance test with RISAH].
Topics: Adult; Angiotensin II; Capillary Permeability; Diabetic Angiopathies; Female; Humans; Male; Middle Aged; Radioisotope Dilution Technique; Serum Albumin, Radio-Iodinated | 1968 |